Why the study?
Polypharmacy in geriatric patients increases the risk of adverse outcomes, necessitating updated screening tools to optimize prescriptions and enhance pharmacotherapy safety and efficacy.
The updated STOPP/START criteria version 3 provides an expanded evidence-based tool to optimize pharmacotherapy and reduce adverse drug reactions in older patients.
Answers are grounded in this paper and cite their sources.
STOPP/START criteria may aid polypharmacy review in geriatrics; leaves open efficacy for reducing adverse outcomes in Russian cohorts.
Polypharmacy in geriatric patients is associated with an increased risk of adverse outcomes. Therefore, several instruments for prescription analysis and optimization can be used to enhance the safety and efficacy of pharmacotherapy in old age population. STOPP/START criteria is one of the most popular screening tools in the Russian Federation and abroad that list potentially inappropriate drugs for use in older patients (STOPP criteria) and potentially prescribed for certain clinical cases (START criteria). Two previous versions of the STOPP/START criteria were published in 2008 and 2015. Released in 2023, the newest (third version) demonstrates the evolution of evidence-based pharmacotherapy for older and oldestold patients, featuring 133 STOPP and 57 START criteria. Expanding the base of STOPP/START criteria should support optimization of prescriptions and reducing ADRs risk in older patients. This article introduces translation of STOPP/START criteria, version 3.
No takes yet. Share an insight, caveat, or question.
Kotovskaya et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: